Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects

Next Previous
X
Search
Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmetramadol (Primary) ; Tramadol
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Syntrix Biosystems

    • Most Recent Events

    • 31 Oct 2019 According to an Syntrix Pharmaceuticals media release, positive desmetramadol trial was featured on the October 2019 cover of The Journal of Pain, the official journal of the American Pain Society.
    • 04 Jun 2019 Results from this and another phase I trial (profile 289610) presented in a Syntrix Biosystems media release.
    • 18 Apr 2019 Results evaluating steady-state pharmacokinetics, efficacy and safety of desmetramadol versus placebo and versus tramadol published in the Journal of Pain

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top